Meeting
2014 ASCO Annual Meeting
Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).
Authors
John F. Forbes
University of Newcastle, ANZBCTG, Calvary Mater Newcastle Hospital, Newcastle, Australia
John F. Forbes , Mitchell Dowsett , Rosie Bradley , James N. Ingle , Tomohiko Aihara , Judith M. Bliss , Francesco Mario Boccardo , Alan S. Coates , R. Charles Coombes , Jack M. Cuzick , Peter Christian Dubsky , Michael Gnant , Manfred Kaufmann , Lucy S Kilburn , Francesco Perrone , Daniel Rea , Beat J. K. Thurlimann , Cornelis J. H. Van De Velde , Christina Davies , Richard G. Gray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 529)
DOI
10.1200/jco.2014.32.15_suppl.529
Abstract #
529
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2012 Breast Cancer Symposium
Estrogen receptor-positive, progesterone receptor-negative tumors: Pathology and outcome correlations from a single-center cohort.
First Author: Oana Danciu
Poster
2023 ASCO Quality Care Symposium
Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ breast cancer from 2001-2016.
First Author: Erin Aiello Bowles
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden